News - Appointments

iTeos Therapeutics Inc has appointed two experienced executives to its board of directors as it advances clinical-stage products for cancer.

Philippe Dro has joined Adjuvant Capital as a partner to help the US firm identify investment opportunities across Europe.

Montis Biosciences BV of Belgium has appointed René Hoet, a molecular immunologist, as chief scientific officer to manage development of cancer therapeutics that target interactions between perivascular macrophages and the tumour va

Pan Cancer T BV has appointed three members to its supervisory board as it makes plans for the development of cell therapies for solid tumours.

Opterion Health AG has appointed Björn Englund as chief executive officer, effective 6 April, succeeding the company’s founder Guido Grentzmann who will oversee scientific affairs.

Sven Zimmermann, a molecular biologist with experience in investment banking, has been appointed chief executive of Inotrem, effective 19 April.

Jonathan Hepple has joined the board of Mission Therapeutics Ltd as a non-executive director following the purchase by Rosetta Capital of a stake in Mission. Dr Hepple is co-founder and partner at Rosetta.

The Dutch vaccine manufacturer Intravacc BV has appointed Nathalie Laarakker as chief financial officer as the company expands its global manufacturing capacity.

Carsten Däweritz has been named chief financial officer, effective 16 April, at the Swiss biotech company Evolva SA which develops and commercialises synthetic biopharmaceutical products.

Elicera Therapeutics AB has appointed the advanced therapy specialist Karin Hoogendoorn to its board of directors to help oversee development of the Swedish company’s CAR T and oncolytic virus therapies for cancer.